Influence of bigeminy drug regimen on short-term effects, quality of life and recurrence rate in children with adenoid hypertrophy
10.3760/cma.j.issn.1673-4904.2018.08.013
- VernacularTitle: 二联药物方案对腺样体肥大患儿近期疗效、生命质量及复发率的影响
- Author:
Jiang QIAN
1
;
Hong ZHANG
;
Yun WEI
;
Seng LI
;
Xilei ZHANG
;
Zu LIU
Author Information
1. Department of Otorhinolaryngology Head and Neck Surgery, Dazhou Integrated Traditional Chinese and Western Medicine Hospital, Sichuan Dazhou 635000, China
- Publication Type:Journal Article
- Keywords:
Hormones;
Child;
Treatment outcome;
Adenoid hypertrophy
- From:
Chinese Journal of Postgraduates of Medicine
2018;41(8):724-727
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the influence of bigeminy drug regimen on short-term clinical effects, quality of life and recurrence rate in children with adenoid hypertrophy.
Methods:One hundred and thirty patients with adenoid hypertrophy were chosen in the period from January 2014 to December 2016. They were randomly divided into 2 groups:control group (65 patients, nasal glucocorticoid used alone) and observation group (65 patients, montelukast sodiumon the basis of control group). The short-term clinical effect, the levels of A/N, serum inflammatory cytokine and OSA-18 score before and after treatment and recurrence rate of 2 groups were compared.
Results:The short-term clinical effects of control group and observation group were separately 73.85%(60/65) and 92.31% (48/65). The levels of A/N after treatment in observation group were significantly lower than those in control group and before treatment: 0.60 ± 0.07 vs. 0.74 ± 0.10, 0.94 ± 0.15 (P<0.05). The levels of IL-1β, IL-2 and IL-4 after treatment in observation group were significantly lower than those in control group and before treatment:IL-1β: (1.50 ± 0.48) ng/L vs. (2.21 ± 0.44), (3.42 ± 0.68) ng/L; IL-2: (21.80 ± 2.08) ng/L vs. (24.28 ± 2.50), (26.61 ± 3.35) ng/L; IL-4: (179.12 ± 35.91) ng/L vs. (244.70 ± 44.42), (284.07 ± 51.87) ng/L (P<0.05). The OSA-18 score after treatment in observation group was significantly lower than that in control group and before treatment (P<0.05). The recurrence rate in control group and observation group was separately 32.31%(21/65) and 15.39%(10/65). The recurrence rate in observation group was significantly lower than that in control group (P<0.05).
Conclusions:Bigeminy drug regimen in the treatment of children with adenoid hypertrophy can efficiently relieve the respiratory obstruction degree, reduce the levels of inflammatory response, improve the quality of daily life and be helpful to prevent long-term recurrence.
